Diabetes Care, Vol 21, Issue 6 977-982, Copyright © 1998 by American Diabetes Association

ARTICLES

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps

V Melki, E Renard, V Lassmann-Vague, S Boivin, B Guerci, H Hanaire-Broutin, J Bringer, P Belicar, N Jeandidier, L Meyer, P Blin, B Augendre-Ferrante and JP Tauber
Service de Diabetologie, Hopital de Rangueil, CHU Toulouse, France.

OBJECTIVE: To compare the efficacy of the short-acting insulin analog lispro (LP) with that of regular insulin in IDDM patients treated with an external pump. RESEARCH DESIGN AND METHODS: Thirty-nine IDDM patients (age, 39.4 +/- 1.5 years; sex ratio, 22M/17W; BMI, 24.4 +/- 0.4 kg/m2; diabetes duration, 22.5 +/- 1.6 years) who were treated by external pump for 5.1 +/- 0.5 years were involved in an open-label, randomized, crossover multicenter study comparing two periods of 3 months of continuous subcutaneous insulin infusion with LP or with Actrapid HM, U-100 (ACT). Boluses were given 0-5 min (LP) or 20-30 min (ACT) before meals. Blood glucose (BG) was monitored before and after the three meals every day. RESULTS: The decrease in HbA1c was more pronounced with LP than with ACT (-0.62 +/- 0.13 vs. -0.09 +/- 0.15%, P = 0.01). BG levels were lower with LP (7.93 +/- 0.15 vs. 8.61 +/- 0.18 mmol/l, P < 0.0001), particularly postprandial BG levels (8.26 +/- 0.19 vs. 9.90 +/- 0.20 mmol/l, P < 0.0001). Standard deviations of all the BG values (3.44 +/- 0.10 vs. 3.80 +/- 0.10 mmol/l, P = 0.0001) and of postprandial BG values (3.58 +/- 0.10 vs. 3.84 +/- 0.10 mmol/l. P < 0.02) were lower with LP. The rate of hypoglycemic events defined by BG < 3.0 mmol/l did not significantly differ between LP and ACT (7.03 +/- 0.94 vs. 7.94 +/- 0.88 per month, respectively), but the rate of occurrences of very low BG, defined as BG < 2.0 mmol/l, were significantly reduced with LP (0.05 +/- 0.05 vs. 0.47 +/- 0.19 per month, P < 0.05). At the end of the study, all but two (95%) of the patients chose LP for the extension phase. CONCLUSIONS: When used in external pumps, LP provides better glycemic control and stability than regular insulin and does not increase the frequency of hypoglycemic episodes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. S. Skyler, S. Ponder, D. F. Kruger, D. Matheson, and C. G. Parkin Is There a Place for Insulin Pump Therapy in Your Practice? Clin. Diabetes, April 1, 2007; 25(2): 50 - 56. [Abstract] [Full Text] [PDF]

				R. Retnakaran, J. Hochman, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c Diabetes Care, November 1, 2004; 27(11): 2590 - 2596. [Abstract] [Full Text] [PDF]

				P. Hammond Continuous subcutaneous insulin infusion: short-term benefits apparent, long-term benefits speculative The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 104 - 108. [Abstract] [PDF]

				K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]

				K. M. Stewart, M. F. Wilson, and J. M. Rider Insulin Delivery Devices Journal of Pharmacy Practice, February 1, 2004; 17(1): 20 - 28. [Abstract] [PDF]

				J. F. Reed III Crossover Designs in Lower Extremity Wounds International Journal of Lower Extremity Wounds, September 1, 2003; 2(3): 158 - 163. [Abstract] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				P. Rossetti, S. Pampanelli, C. Fanelli, F. Porcellati, E. Costa, E. Torlone, L. Scionti, and G. B. Bolli Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime Diabetes Care, May 1, 2003; 26(5): 1490 - 1496. [Abstract] [Full Text] [PDF]

				B. Guerci, M. Benichou, M. Floriot, P. Bohme, S. Fougnot, P. Franck, and P. Drouin Accuracy of an Electrochemical Sensor for Measuring Capillary Blood Ketones by Fingerstick Samples During Metabolic Deterioration After Continuous Subcutaneous Insulin Infusion Interruption in Type 1 Diabetic Patients Diabetes Care, April 1, 2003; 26(4): 1137 - 1141. [Abstract] [Full Text] [PDF]

				L. Meyer, P. Bohme, I. Delbachian, P. Lehert, N. Cugnardey, P. Drouin, and B. Guerci The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients Diabetes Care, December 1, 2002; 25(12): 2153 - 2158. [Abstract] [Full Text] [PDF]

				J. H. DeVries, F. J. Snoek, P. J. Kostense, N. Masurel, and R. J. Heine A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control Diabetes Care, November 1, 2002; 25(11): 2074 - 2080. [Abstract] [Full Text] [PDF]

				J. Pickup, M. Mattock, and S. Kerry Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials BMJ, March 23, 2002; 324(7339): 705 - 705. [Abstract] [Full Text] [PDF]

				B. Bode, R. Weinstein, D. Bell, J. McGill, D. Nadeau, P. Raskin, J. Davidson, R. Henry, W.-C. Huang, and R. R. Reinhardt Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion: A randomized study in type 1 diabetes Diabetes Care, March 1, 2002; 25(3): 439 - 444. [Abstract] [Full Text] [PDF]

				J. Pickup and H. Keen Continuous Subcutaneous Insulin Infusion at 25 Years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes Diabetes Care, March 1, 2002; 25(3): 593 - 598. [Abstract] [Full Text] [PDF]

				M. J. Lenhard and G. D. Reeves Continuous Subcutaneous Insulin Infusion: A Comprehensive Review of Insulin Pump Therapy Arch Intern Med, October 22, 2001; 161(19): 2293 - 2300. [Abstract] [Full Text] [PDF]

				E. Tsui, A. Barnie, S. Ross, R. Parkes, and B. Zinman Intensive Insulin Therapy With Insulin Lispro: A randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection Diabetes Care, October 1, 2001; 24(10): 1722 - 1727. [Abstract] [Full Text] [PDF]

				J. Pickup and H. Keen Continuous subcutaneous insulin infusion in type 1 diabetes BMJ, May 26, 2001; 322(7297): 1262 - 1263. [Full Text] [PDF]

				H. P. Chase, T. Lockspeiser, B. Peery, M. Shepherd, T. MacKenzie, J. Anderson, and S. K. Garg The Impact of the Diabetes Control and Complications Trial and Humalog Insulin on Glycohemoglobin Levels and Severe Hypoglycemia in Type 1 Diabetes Diabetes Care, March 1, 2001; 24(3): 430 - 434. [Abstract] [Full Text]

				B. Guerci, L. Meyer, A. Sallé, A. Charrié, B. Dousset, O. Ziegler, and P. Drouin Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2673 - 2678. [Abstract] [Full Text]